Scarica l'app Stockscreener
2.28
7.55%
0.16
Dopo l'orario di chiusura:
2.27
-0.010
-0.44%
Annovis Bio Inc Borsa (ANVS) Ultime notizie
ANVS.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat
Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents - Quiver Quantitative
Annovis Bio receives patent for buntanetap in brain infections - Investing.com
Annovis Secures U.S. Patent for Buntanetap in the - globenewswire.com
ANVS Stock Price and Chart — NYSE:ANVS - TradingView
ANVS.N PE Ratio & Valuation, Is ANVS.N Overvalued - Intellectia AI
Annovis Publishes Historical Review of Buntanetap in The Scientist - Bitget
Bearish Setup: Will Annovis Bio Inc stock hit new highs in YEAR2026 Technicals & Growth-Oriented Investment Plans - baoquankhu1.vn
Annovis Bio Inc Stock: Phase 3 Progress in Alzheimer's and Parkinson's Therapies Drives Investor Foc - AD HOC NEWS
ANVS Technical Analysis | Trend, Signals & Chart Patterns | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study - MyChesCo
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - au.investing.com
Annovis Bio CFO departs, CEO appointed as acting CFO - Investing.com
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement. - Bitget
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Annovis Bio, Inc. Announces Change of Chief Financial Officer - MarketScreener
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Reports 2025 Results, Advances Buntanetap Trials - MyChesCo
If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Rankings: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Meme Stocks: Will Annovis Bio Inc benefit from rising consumer demand2026 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring - Intellectia AI
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring By Investing.com - Investing.com India
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - The Manila Times
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):